HC Wainwright Reiterates Buy Rating for Atyr PHARMA (NASDAQ:ATYR)

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note published on Monday,Benzinga reports. The firm currently has a $35.00 price objective on the stock.

Several other equities research analysts also recently issued reports on ATYR. Leerink Partners started coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target for the company. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Stock Up 5.2%

Shares of Atyr PHARMA stock opened at $3.44 on Monday. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66. The business has a 50-day moving average of $3.26 and a two-hundred day moving average of $3.41. The company has a market capitalization of $306.17 million, a P/E ratio of -3.66 and a beta of 0.79. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, equities analysts predict that Atyr PHARMA will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ATYR. Group One Trading LLC bought a new position in Atyr PHARMA in the fourth quarter valued at approximately $26,000. Alterna Wealth Management Inc. bought a new position in Atyr PHARMA in the fourth quarter valued at approximately $36,000. Victory Capital Management Inc. bought a new position in Atyr PHARMA in the fourth quarter valued at approximately $37,000. Y Intercept Hong Kong Ltd bought a new position in Atyr PHARMA in the first quarter valued at approximately $38,000. Finally, Raymond James Financial Inc. bought a new position in Atyr PHARMA in the fourth quarter valued at approximately $39,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.